PiggyBac-Engineered Membrane-Bound IL7 TILs Combined with Anti‑PD‑1 Antibody Demonstrates Efficacy in Recurrent Ovarian Cancer: A First-in-Human Phase I Trial
The GC203 regimen demonstrated a favorable safety profile.
The GC203 regimen demonstrated a favorable safety profile.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Scientists discover why cancer drugs don’t work for everyone
- Epithelial ovarian cancer: prevention, diagnosis, and treatment
- Gynecologic Cancer InterGroup Consensus Recommendations on Clinical Research in Ovarian Cancer
- Why anti‑estrogen therapy fails in ovarian cancer, and how to make it work
- Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements